Healthy volunteers test new cancer Drug's body processing
NCT ID NCT07044271
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study enrolled 120 healthy volunteers to measure how much olomorasib enters the bloodstream and how quickly the body eliminates it. Participants took a single dose of the drug by mouth and stayed overnight at the research center for 10 nights over about 7 weeks. The results will guide future dosing for patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
olomorasib (LY3537982)
What this could lead to
If successful, this study will help determine the right dose and formulation of olomorasib for future trials in patients.
What could go wrong
This is an early-stage study in healthy people, not patients. Results may not predict how the drug works in people with disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON
Salt Lake City, Utah, 84124, United States
-
ICON Early Phase Services
San Antonio, Texas, 78209, United States